Evidence map›Paper›PMID 24627603›Full record

ArticleWorld journal of gastroenterology2014

Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma.

Tomoaki Ishihara, Motoh Iwasa, Hideaki Tanaka, Masahiko Kaito, Jiro Ikoma, Toshiya Shibata, Yoshiyuki Takei

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tomoaki IshiharaTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Motoh IwasaTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Hideaki TanakaTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Masahiko KaitoTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Jiro IkomaTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Toshiya ShibataTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Yoshiyuki TakeiTomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
Tomitahama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the usefulness of branched-chain amino acids (BCAA) before transarterial chemoembolization (TACE) or radiofrequency ablation (RFA).

methodsWe investigated the usefulness of pre-intervention with BCAAs by comparing patients treated with BCAAs at 12.45 g/d orally for at least 2 wk before TACE or RFA and those not receiving such pretreatment. A total of 270 patients with hepatocellular carcinoma complicated by cirrhosis were included in the study. Mean changes from baseline (Δ) in serum albumin (Alb), C-reactive protein (CRP), and transaminase levels, as well as peak body temperature were also determined and compared at days 2, 5, and 10 after the start of TACE or RFA.

resultsIn patients who underwent TACE or RFA, BCAA pre-intervention significantly suppressed the development of post- intervention hypoalbuminemia and reduced inflammatory reactions during the subsequent clinical course. After TACE, the ΔAlb peaked on day 2, remained constantly lower in BCAA-treated patients, compared to the control group, and was -0.13 ± 0.42 g/dL in BCAA-treated patients and -0.33 ± 0.51 g/dL in untreated patients on day 10. The ΔCRP was also significantly lower in BCAA-treated patients on days 2, 5 and 10 after TACE. Like the trends noted after TACE, a similar tendency was noted as to the ΔAlb and ΔCRP after RFA. The changes in serum Alb level were inversely correlated with CRP changes; therefore, a possible involvement of the anti-inflammatory effect of BCAAs was inferred as a factor contributory to the suppression of decrease in serum Alb level.

conclusionPre-intervention with BCAAs may hasten the recovery of serum Alb level and mitigate post-operative complications in patients undergoing TACE or RFA.

Indexed as

Catheter AblationChemoembolization, TherapeuticDietary SupplementsAdministration, OralAgedAged, 80 and overAmino Acids, Branched-ChainBody Temperature RegulationCarcinoma, HepatocellularC-Reactive ProteinDrug Administration ScheduleFemaleHumansHypoalbuminemiaLiver NeoplasmsMaleALB protein, humanAmino Acids, Branched-ChainC-Reactive ProteinSerum AlbuminSerum Albumin, HumanTransaminasesBranched-chain amino acidsCirrhosisHepatocellular carcinomaHypoalbuminemiaRadiofrequency ablationTransarterial chemoembolization

Identifiers

PMID24627603
PMCPMC3949276
OpenAlexW2128047778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.